[
{"Name" : "CHF PSZ GMENU HEART FAILURE MANAGEMENT MENU", "Term" : "created 4/18/23 per LEAF request #330, submitted by Crook, to improve medication management of Heart Failure and to align prescribing with VA/DoD guidelines  MTB-CAC", "DisplayText" : "Heart Failure Management Menu  ", "Version" : "CHF", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "Lifestyle Changes and Management of Comorbidities (strong for...)", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Text" : "    -Patients should maintain a healthy lifestyle including regular physical"}, 
{"Row" : 4, "Column" : 1, "Text" : "        activity, maintaining a normal weight, healthy dietary patterns (i.e.,"}, 
{"Row" : 5, "Column" : 1, "Text" : "        Mediterranean, whole grain, plant-based, and DASH diets), and avoiding smoking"}, 
{"Row" : 6, "Column" : 1, "Text" : "    -Manage hypertension and titrate goal-directed medical therapy to  maximally"}, 
{"Row" : 7, "Column" : 1, "Text" : "        tolerated target doses (morbidity benefit in Preserved EF)"}, 
{"Row" : 8, "Column" : 1, "Text" : "    -In patients with suspicion of sleep-disordered breathing, conduct a formal"}, 
{"Row" : 9, "Column" : 1, "Text" : "        sleep assessment to diagnose/differentiate between obstructive and central"}, 
{"Row" : 10, "Column" : 1, "Text" : "       sleep apnea (level 2a recommendation)"}, 
{"Row" : 11, "Column" : 1, "Text" : "    -In patients with obstructive sleep apnea, consider using a CPAP machine to"}, 
{"Row" : 12, "Column" : 1, "Text" : "        improve sleep quality and decrease daytime sleepiness (level 2a recommendation)"}, 
{"Row" : 13, "Column" : 1, "Text" : "    -Manage atrial fibrillation, if present, for symptom improvement (level 2a"}, 
{"Row" : 14, "Column" : 1, "Text" : "        recommendation for Preserved EF)"}, 
{"Row" : 17, "Column" : 1, "Text" : "Guideline Directed Medical Medication Management Recommendations For:", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "-SGLT-2i, ACEI, ARB, ARNI:"}, 
{"Row" : 37, "Column" : 1, "Text" : "-Mineralocorticoid Receptor Antagonists:"}, 
{"Row" : 1, "Column" : 2, "Text" : "REFERRALS:", "Header" : 1}, 
{"Row" : 3, "Column" : 2, "Item" : "CHF GMRCZ PROSTHETICS & SENSORY AIDS REQUEST", "DisplayText" : "PROSTHETICS & SENSORY AIDS REQUEST", "Text" : "    BP cuff"},
{"Row" : 4, "Column" : 2, "Item" : "CHF GMRCZ PROSTHETICS & SENSORY AIDS REQUEST", "DisplayText" : "PROSTHETICS & SENSORY AIDS REQUEST", "Text" : "    Scale"},
{"Row" : 5, "Column" : 2, "Item" : "CHF GMRCZ NUTRITION EDUCATION CONSULT OUTPATIENT", "DisplayText" : "NUTRITION EDUCATION/MEDICAL NUTRITION THERAPY CONSULT OUTPATIENT", "Text" : "    Nutrition Consult"},
{"Row" : 6, "Column" : 2, "Item" : "CHF GMRCZ HOME TELEHEALTH ENROLLMENT OUTPT", "DisplayText" : "CCHT/HOME TELEHEALTH", "Text" : "    Home Telehealth"},
{"Row" : 7, "Column" : 2, "Item" : "CHF GMRCTZ WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "WEIGHT MANAGMENT OUTPATIENT CONSULT", "Text" : "    Weight Management"},
{"Row" : 8, "Column" : 2, "Item" : "CHF GMRCTZ TOBACCO CESSATION PROGRAM OUTPATIENT CONSULT", "DisplayText" : "TOBACCO CESSATION PROGRAM OUTPATIENT CONSULT", "Text" : "    Tobacco Cessation"},
{"Row" : 9, "Column" : 2, "Item" : "CHF GMRCTZ HOME-BASED CARDIAC REHAB OUTPT CONSULT", "DisplayText" : "Home-Based Cardiac Rehab Outpt Consult", "Text" : "    Home-Based Cardiac Rehab (1a recommendation)"},
{"Row" : 10, "Column" : 2, "Item" : "CHF GMRCZ SLEEP MEDICINE CONSULT OUTPT", "DisplayText" : "SLEEP MEDICINE CONSULT OUTPT", "Text" : "    Sleep Medicine Consult Outpatient"},
{"Row" : 11, "Column" : 2, "Item" : "CHF GMRCZ ECHOCARDIOGRAM CONSULT OUTPT", "DisplayText" : "ECHOCARDIOGRAM CONSULT OUTPT", "Text" : "    Echocardiogram"},
{"Row" : 12, "Column" : 2, "Item" : "CHF GMRCZ MEDICINE CARDIOLOGY CONSULT OUTPT", "DisplayText" : "MEDICINE CARDIOLOGY CONSULT OUTPT", "Text" : "    Cardiology Outpatient"},
{"Row" : 13, "Column" : 2, "Item" : "CHF GMRCTZ PALLIATIVE CARE CONSULT OUTPATIENT", "DisplayText" : "PALLIATIVE CARE CONSULT", "Text" : "    Palliative Care Outpatient-Stage D"},
{"Row" : 17, "Column" : 2, "Text" : "CHF Stages for Reference:", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "Stage A: Risk factors for HF present (but no current symptoms/signs)"}, 
{"Row" : 21, "Column" : 2, "Text" : "Stage B (Pre-Heart Failure): No current or previous symptoms, but evidence of"}, 
{"Row" : 22, "Column" : 2, "Text" : " any of the following: structural heart disease, evidence of increased filling"}, 
{"Row" : 23, "Column" : 2, "Text" : " pressures, risk factors + (increased natriuretic peptide levels or elevated"}, 
{"Row" : 24, "Column" : 2, "Text" : " troponin in absence of competing diagnosis)"}, 
{"Row" : 26, "Column" : 2, "Text" : "Stage C (Symptomatic Heart Failure): Current or previous symptoms/signs of HF"}, 
{"Row" : 28, "Column" : 2, "Text" : "Stage D (Advanced Heart Failure): Marked HF that interfere with daily life and"}, 
{"Row" : 29, "Column" : 2, "Text" : " with recurrent hospitalizations despite attempts to optimize GDMT"}, 
{"Row" : 19, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE PRESERVED EF V2", "DisplayText" : "Heart Failure Management - Recommendations for Preserved EF", "Text" : "    Preserved EF (LVEF >= 50%)..."},
{"Row" : 23, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE MILDLY-REDUCED EF v2", "DisplayText" : "Heart Failure Management Recommendations for Mildly-reduced EF", "Text" : "    Mildly-reduced EF (LVEF 41-49%)..."},
{"Row" : 21, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE REDUCED EF V2", "DisplayText" : "    Reduced EF (LVEF <= 40%) or HF with Improved EF..."},
{"Row" : 27, "Column" : 1, "Text" : "LABS (baseline and after initiation/change):", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "CHF LRTZ CHEM8(SP) TODAY", "DisplayText" : " Chem 7 (today)", "Text" : "   Chem 7 (today)"},
{"Row" : 31, "Column" : 1, "Item" : "CHF LRTZ CHEM8(SP) 7 DAYS", "DisplayText" : " Chem 7 (7 days)", "Text" : "   Chem 7 (7 days)"},
{"Row" : 33, "Column" : 1, "Text" : "-Loop diuretics or Mineralocorticoids Receptor Antagonists:"}, 
{"Row" : 34, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF TODAY", "DisplayText" : " Chem 7 + MAG Today", "Text" : "         Chem 7 + Magnesium (today)"},
{"Row" : 35, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 7 DAYS", "DisplayText" : " Chem 7 + Mag 7 Days", "Text" : "         Chem 7 + Magnesium (7 days)"},
{"Row" : 38, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 28 DAYS", "DisplayText" : " Chem 7 + Mag 28 Days", "Text" : "         Chem 7 + Magnesium (28 days)"},
{"Row" : 39, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 6 MONTHS", "DisplayText" : " Chem 7 + Mag 6 months", "Text" : "         Chem 7 + Magnesium (6 months)"}
]},
{"Name" : "CHF PSZ GMENU HEART FAILURE MILDLY-REDUCED EF v2", "Term" : "created 4/18/23 per LEAF request #330, submitted by Crook, to improve medication management of Heart Failure and to align prescribing with VA/DoD guidelines  MTB-CAC", "DisplayText" : "Heart Failure Management Recommendations for Mildly-reduced EF  ", "Version" : "CHF", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "Recommendations for Mildly-reduced EF (LVEF 41-49%)", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Text" : "(Order by strength of recommendation - Top to Bottom, then to next column)"}, 
{"Row" : 5, "Column" : 1, "Text" : "SGLT2i (Level 2a recommendation)", "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Text" : "    -Hospitalization and mortality benefit"}, 
{"Row" : 7, "Column" : 1, "Text" : "    -Contraindicated for dialysis, pregnant/nursing, DM-1, high risk for"}, 
{"Row" : 8, "Column" : 1, "Text" : "       ketoacidosis, hx of (pancreatic surgery, pancreastitis, or alcohol abuse)"}, 
{"Row" : 9, "Column" : 1, "Text" : "    -Increased risk of UTIs and genital mycotic infections"}, 
{"Row" : 10, "Column" : 1, "Text" : "    -Reduced efficacy with eGFR <20"}, 
{"Row" : 15, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), ACE INHIBITOR (ACEI),", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "OR ANGIOTENSIN RECEPTOR BLOCKER (ARB)  (Level 2b recommendation)", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "    -Consider initiation for hospitalization and mortality benefit in  patients"}, 
{"Row" : 18, "Column" : 1, "Text" :      " with current or previously symptomatic HF"}, 
{"Row" : 19, "Column" : 1, "Text" : "    -ARNI and ACEI contraindicated with hx of angioedema"}, 
{"Row" : 20, "Column" : 1, "Text" : "    -Additional benefit in diabetes with microalbuminuria and chronic kidney"}, 
{"Row" : 21, "Column" : 1, "Text" : "      disease (CKD)"}, 
{"Row" : 22, "Column" : 1, "Text" : "    -Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 24, "Column" : 1, "Text" : "    ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI):"}, 
{"Row" : 12, "Column" : 1, "Item" : "CHF PSOZ EMPAGLIFLOZIN 12.5MG PO DAILY", "DisplayText" : "           Empagliflozin 12.5mg (Target 12.5mg daily)"},
{"Row" : 25, "Column" : 1, "Text" : "     *Do not administer within 36 hours of ACEI"}, 
{"Row" : 27, "Column" : 1, "Item" : "CHF PSOZ ENTRESTO __ MG (OUTPT)", "DisplayText" : "SACUBITRIL/VALSARTAN (ENTRESTO)", "Text" : "           Sacubitril/valsartan __ mq (Target 97/103mg BID"},
{"Row" : 28, "Column" : 1, "Text" : "             If no current ACEI/ARB use or if taking low dose ACEI/ARB: Initiate"}, 
{"Row" : 29, "Column" : 1, "Text" : "                                 24mg/26mg BID"}, 
{"Row" : 30, "Column" : 1, "Text" : "         If current use of moderate dose ACEI/ARB: Initiate 49mg/51mg BID"}, 
{"Row" : 32, "Column" : 1, "Text" : "ACE INHIBITORS (ACEI):"}, 
{"Row" : 33, "Column" : 1, "Text" : "  *Failure/Contraindication to ARNI"}, 
{"Row" : 35, "Column" : 1, "Item" : "CHF PSOZ LISINOPRIL __MG DAILY (CHF)", "DisplayText" : "            Lisinopril __mg (Initiate 2.5-5mg daily, Target 20-40mg daily)", "Text" :""},
{"Row" : 37, "Column" : 1, "Item" : "CHF PSOZ ENALAPRIL ___MG BID (CHF)", "DisplayText" : "            Enalapril __mg (Initiate 2.5mg BID, Target 10-20mg BID)"},
{"Row" : 39, "Column" : 1, "Item" : "CHF PSOZ CAPTOPRIL __MG TID (CHF)", "DisplayText" : "            Captopril __mg (Initiate 6.25mg TID, Target 50mg TID)", "Text" :""},
{"Row" : 42, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR BLOCKER (ARB):"}, 
{"Row" : 43, "Column" : 1, "Text" : "  *Failure/Contraindication to ARNI and ACEI"}, 
{"Row" : 45, "Column" : 1, "Item" : "CHF PSOZ LOSARTAN __MG DAILY (CHF)", "DisplayText" : "            Losartan __mg (Initiate 25-50mg daily, Target 50-150mg daily)"},
{"Row" : 47, "Column" : 1, "Item" : "CHF PSOZ VALSARTAN __MG (CHF)", "DisplayText" : "            Valsartan __mg (Initiate 20-40mg daily, Target 160mg BID)"},
{"Row" : 49, "Column" : 1, "Item" : "CHF PSOZ CANDESARTAN __MG DAILY (CHF)", "DisplayText" : "            Candesartan __mg (Initiate 4-8mg daily, Target 32mg daily)"},
{"Row" : 7, "Column" : 3, "Text" : "-SGLT-2i, ACEI, ARB, ARNI:"}, 
{"Row" : 15, "Column" : 3, "Text" : "-Mineralocorticoid Receptor Antagonists:"}, 
{"Row" : 5, "Column" : 2, "Text" : "MINERALOCORTICOID RECEPTOR ANTAGONISTS (Level 2b recommendation)", "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Text" : "    -Hospitalization benefit, especially in patients with EF closer to 50%"}, 
{"Row" : 7, "Column" : 2, "Text" : "    -Not recommended for GFR<30 (clinical trials excluded patients with serum"}, 
{"Row" : 8, "Column" : 2, "Text" : " creatinine =2.5 mg/dL) or baseline K+ >5"}, 
{"Row" : 9, "Column" : 2, "Text" : "    -Monitor K+ closely especially if also on ARNI, ACEI, or ARB"}, 
{"Row" : 10, "Column" : 2, "Text" : "    -Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 12, "Column" : 2, "Item" : "CHF PSOZ SPIRONOLACTONE __MG DAILY (CHF)", "DisplayText" : "            Spironolactone __mg (Initiate 12.5-25mg daily, Target 25-50mg daily)", "Text" :""},
{"Row" : 14, "Column" : 2, "Text" : "    -If unable to use spironolactone due to gynecomastia or sexual side effects:"}, 
{"Row" : 15, "Column" : 2, "Item" : "CHF PSOZ EPLERENONE __MG DAILY (CHF)", "DisplayText" : "            Eplerenone __mg (Initiate 25mg daily, Target 50mg daily)", "Text" :""},
{"Row" : 17, "Column" : 2, "Text" : "BETA BLOCKERS (Level 2b recommendation)", "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Text" : "    -Mortality and hospitalization benefit"}, 
{"Row" : 19, "Column" : 2, "Text" : "    -Initiate in Stage B and Stage C"}, 
{"Row" : 20, "Column" : 2, "Text" : "    -Avoid/use caution with 2nd/3rd degree heart block"}, 
{"Row" : 21, "Column" : 2, "Text" : "    -Caution with resting bradycardia"}, 
{"Row" : 23, "Column" : 2, "Item" : "CHF PSOZ CARVEDILOL __MG BID (CHF)", "DisplayText" : "          Carvedilol __mg (Initiate 3.125mg BID)", "Text" :""},
{"Row" : 24, "Column" : 2, "Text" : "             If weight <=85kg: Target 25mg BID"}, 
{"Row" : 25, "Column" : 2, "Text" : "             If weight >85kg: Target 50mg BID"},
{"Row" : 27, "Column" : 2, "Item" : "CHF PSOZ METOPROLOL SUCCINATE __MG DAILY (CHF)", "DisplayText" : "          Metoprolol Succinate __mg (Initiate 12.5mg - 25mg daily, Target 200mg)"},
{"Row" : 29, "Column" : 2, "Text" : "    -If failed carvedilol and metoprolol:"}, 
{"Row" : 31, "Column" : 2, "Text" : "             Note: smallest commercially available tablet strength is 5mg"}, 
{"Row" : 30, "Column" : 2, "Item" : "CHF PSOZ BISOPROLOL __MG DAILY (CHF)", "DisplayText" : "           Bisoprolol __mg (Initiate 1.25mg daily, Target 10mg)"},
{"Row" : 34, "Column" : 2, "Text" : "LOOP DIURETICS", "Header" : 1}, 
{"Row" : 35, "Column" : 2, "Text" : "                    -Symptom benefit"}, 
{"Row" : 36, "Column" : 2, "Text" : "    -Preferred diuretic for most patients with fluid retention and congestive"}, 
{"Row" : 37, "Column" : 2, "Text" : "         symptoms"}, 
{"Row" : 38, "Column" : 2, "Text" : "    -May cause dehydration"}, 
{"Row" : 39, "Column" : 2, "Text" : "                   -Monitor K+ and electrolytes closely"}, 
{"Row" : 40, "Column" : 2, "Text" : "    -May use thiazide instead of a loop if patient is also hypertensive and only"}, 
{"Row" : 41, "Column" : 2, "Text" : " mold fluid retention, if CrCl>30"}, 
{"Row" : 42, "Column" : 2, "Item" : "CHF PSOZ FUROSEMIDE __MG (CHF)", "DisplayText" : "            Furosemide __mg (Initiate 20-40mg daily or BID, Max 600mg/day)", "Text" :""},
{"Row" : 44, "Column" : 2, "Item" : "CHF PSOZ BUMETANIDE __MG (CHF)", "DisplayText" : "            Bumetanide __mg (Initiate 0.5-1mg daily or BID, Max 10mg/day)"},
{"Row" : 46, "Column" : 2, "Text" : "    -If failed furosemide and bumetanide:"}, 
{"Row" : 48, "Column" : 2, "Item" : "CHF GMRCZ PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "DisplayText" : "PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "Text" : "   PADR for torsemide"},
{"Row" : 50, "Column" : 2, "Text" : "    -If no response to moderate-high dose loop diuretic:"}, 
{"Row" : 51, "Column" : 2, "Item" : "CHF PSOZ METOLAZONE __MG (CHF)", "DisplayText" : "            Metolazone __mg (Initiate 2.5mg 2-3 time a week)"},
{"Row" : 5, "Column" : 3, "Text" : "LABS (baseline and after initiation/change):", "Header" : 1}, 
{"Row" : 8, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) TODAY", "DisplayText" : "Chem 7 (today)", "Text" : "    Chem 7 (today)"},
{"Row" : 9, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) 7 DAYS", "DisplayText" : "Chem 7 (7 days)", "Text" : "    Chem 7 (7 days)"},
{"Row" : 11, "Column" : 3, "Text" : "    -Loop diuretics or Mineralocorticoids Receptor Antagonists:"}, 
{"Row" : 12, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF TODAY", "DisplayText" : "Chem 7 + MAG Today", "Text" : "    Chem 7 + Magnesium (today)"},
{"Row" : 13, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 7 DAYS", "DisplayText" : "Chem 7 + Mag 7 Days", "Text" : "    Chem 7 + Magnesium (7 days)"},
{"Row" : 16, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 28 DAYS", "DisplayText" : "Chem 7 + Mag 28 Days", "Text" : "    Chem 7 + Magnesium (28 days)"},
{"Row" : 17, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 6 MONTHS", "DisplayText" : "Chem 7 + Mag 6 months", "Text" : "    Chem 7 + Magnesium (6 months)"}
]},
{"Name" : "CHF PSZ GMENU HEART FAILURE PRESERVED EF V2", "Term" : "created 4/18/23 per LEAF request #330, submitted by Crook, to improve medication management of Heart Failure and to align prescribing with VA/DoD guidelines  MTB-CAC", "DisplayText" : "Heart Failure Management - Recommendations for Preserved EF  ", "Version" : "CHF", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "Recommendations for Preserved EF (LVEF >= 50%)", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Text" : "(Order by strength of recommendation - Top to Bottom, then to next column)"}, 
{"Row" : 5, "Column" : 1, "Text" : "SGLT2i (Level 2a recommendation)", "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Text" : "    -Consider initiation for hospitalization and mortality benefit"}, 
{"Row" : 7, "Column" : 1, "Text" : "    -Contraindicated for dialysis, pregnant/nursing, DM-1, high risk for"}, 
{"Row" : 8, "Column" : 1, "Text" : "       ketoacidosis, hx of (pancreatic surgery, pancreatitis, or alochol abuse)"}, 
{"Row" : 9, "Column" : 1, "Text" : "    -Increased risk of UTIs and genital mycotic infections"}, 
{"Row" : 10, "Column" : 1, "Text" : "    -Reduced efficacy with eGFR <20"}, 
{"Row" : 14, "Column" : 1, "Text" : "Labs. Check at baseline and within 7-10 days of initiation"}, 
{"Row" : 18, "Column" : 1, "Text" : "MINERALOCORTICOID RECEPTOR ANTAGONISTS (Level 2b recommendation)", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "    -Consider initiation for hospitalization benefit, especially in patients with EF"}, 
{"Row" : 20, "Column" : 1, "Text" : "       closer to 50%"}, 
{"Row" : 21, "Column" : 1, "Text" : "    -Not recommended for GFR<30 (clinical trials excluded patients with serum"}, 
{"Row" : 22, "Column" : 1, "Text" : "       creatinine >=2.5 mg/dL) or baseline K+ >5"}, 
{"Row" : 23, "Column" : 1, "Text" : "    -Monitor K+ closely, especially if also on ARNI, ACEI, or ARB"}, 
{"Row" : 24, "Column" : 1, "Text" : "    -Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 28, "Column" : 1, "Text" : "    -If unable to use spironolactone due to gynecomastia or sexual side effects:"}, 
{"Row" : 7, "Column" : 3, "Text" : "-SGLT-2i, ACEI, ARB, ARNI:"}, 
{"Row" : 15, "Column" : 3, "Text" : "                 -Mineralocorticoid Receptor Antagonists:"}, 
{"Row" : 4, "Column" : 2, "Text" : "ANGIOTENSIN RECEPTOR BLOCKER (ARB) or ANGIOTENSIN RECEPTOR NEPRILYSIN", "Header" : 1}, 
{"Row" : 5, "Column" : 2, "Text" : " INHIBITOR (ARNI)  (Level 2b recommendation)", "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Text" : "    -Consider initiation for hospitalization benefit, especially in patients with EF"}, 
{"Row" : 7, "Column" : 2, "Text" : "       closer to 50%"}, 
{"Row" : 8, "Column" : 2, "Text" : "    -ARNI contraindicated with hx of angiodema"}, 
{"Row" : 9, "Column" : 2, "Text" : "    -Additional benefit in diabetes with microalbuminuria"}, 
{"Row" : 10, "Column" : 2, "Text" : "    -Additional benefit in chronic kidney disease (CKD)"}, 
{"Row" : 11, "Column" : 2, "Text" : "    -Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 13, "Column" : 2, "Text" : "    ANGIOTENSIN RECEPTOR BLOCKER (ARB):"}, 
{"Row" : 21, "Column" : 2, "Text" : "    ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI):"}, 
{"Row" : 22, "Column" : 2, "Text" : "      *Do not administer within 36 hours of ACEI"}, 
{"Row" : 26, "Column" : 2, "Text" : "                          If no current ACEI/ARB use or if taking low dose ACEI/ARB: Initiate"}, 
{"Row" : 27, "Column" : 2, "Text" : "                   24mg/26mg BID"}, 
{"Row" : 28, "Column" : 2, "Text" : "                                    If current use of moderate dose ACEI/ARB: Initiate 49mg/51mg BID"}, 
{"Row" : 31, "Column" : 2, "Text" : "LOOP DIURETICS", "Header" : 1}, 
{"Row" : 32, "Column" : 2, "Text" : "    -Symptom benefit"}, 
{"Row" : 33, "Column" : 2, "Text" : "    -Initiate in patients with fluid retention and congestive symptoms"}, 
{"Row" : 34, "Column" : 2, "Text" : "    -May cause dehydration"}, 
{"Row" : 35, "Column" : 2, "Text" : "    -Monitor K+ and electrolytes closely"}, 
{"Row" : 36, "Column" : 2, "Text" : "    -Consider using a thiazide instead of a loop if patient is also hypertensive to"}, 
{"Row" : 37, "Column" : 2, "Text" : "       help manage HTN and congestive symptoms"}, 
{"Row" : 43, "Column" : 2, "Text" : "    -If failed furosemide and bumetanide:"}, 
{"Row" : 46, "Column" : 2, "Text" : "    -If no response to moderate-high dose loop diuretic:"}, 
{"Row" : 12, "Column" : 1, "Item" : "CHF PSOZ EMPAGLIFLOZIN 12.5MG PO DAILY", "DisplayText" : "             Empagliflozin 12.5mg (Target 12.5mg daily)"},
{"Row" : 26, "Column" : 1, "Item" : "CHF PSOZ SPIRONOLACTONE __MG DAILY (CHF)", "DisplayText" : "             Spironolactone __mg (Initiate 12.5-25mg daily, Target 25-50mg daily)", "Text" :""},
{"Row" : 29, "Column" : 1, "Item" : "CHF PSOZ EPLERENONE __MG DAILY (CHF)", "DisplayText" : "            Eplerenone __mg (Initiate 25mg daily, Target 50mg daily)", "Text" :""},
{"Row" : 15, "Column" : 2, "Item" : "CHF PSOZ LOSARTAN __MG DAILY (CHF)", "DisplayText" : "            Losartan __mg (Initiate 25-50mg daily, Target 50-150mg daily)"},
{"Row" : 17, "Column" : 2, "Item" : "CHF PSOZ VALSARTAN __MG (CHF)", "DisplayText" : "            Valsartan __mg (Initiate 20-40mg daily, Target 160mg BID)"},
{"Row" : 19, "Column" : 2, "Item" : "CHF PSOZ CANDESARTAN __MG DAILY (CHF)", "DisplayText" : "            Candesartan __mg (Initiate 4-8mg daily, Target 32mg daily)"},
{"Row" : 24, "Column" : 2, "Item" : "CHF PSOZ ENTRESTO __ MG (OUTPT)", "DisplayText" : "SACUBITRIL/VALSARTAN (ENTRESTO)", "Text" : "            Sacubitril/valsartan __ mq (Target 97/103mg BID)"},
{"Row" : 41, "Column" : 2, "Item" : "CHF PSOZ BUMETANIDE __MG (CHF)", "DisplayText" : "            Bumetanide __mg (Initiate 0.5-1mg daily or BID, Max 10mg/day)"},
{"Row" : 44, "Column" : 2, "Item" : "CHF GMRCZ PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "DisplayText" : "PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "Text" : "   PADR for torsemide"},
{"Row" : 47, "Column" : 2, "Item" : "CHF PSOZ METOLAZONE __MG (CHF)", "DisplayText" : "            Metolazone __mg (Initiate 2.5mg 2-3 time a week)"},
{"Row" : 15, "Column" : 1, "Item" : "CHF LRTZ CHEM8(SP)", "DisplayText" : "Chem 8(BMP)", "Text" : "    Chem 7 (monitor renal function and glucose)"},
{"Row" : 39, "Column" : 2, "Item" : "CHF PSOZ FUROSEMIDE __MG (CHF)", "DisplayText" : "            Furosemide __mg (Initiate 20-40mg daily or BID, Max 600mg/day)", "Text" :""},
{"Row" : 5, "Column" : 3, "Text" : "LABS (baseline and after initiation/change):", "Header" : 1}, 
{"Row" : 8, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) TODAY", "DisplayText" : " Chem 7 (today)", "Text" : "   Chem 7 (today)"},
{"Row" : 9, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) 7 DAYS", "DisplayText" : " Chem 7 (7 days)", "Text" : "  Chem 7 (7 days)"},
{"Row" : 11, "Column" : 3, "Text" : "-Loop diuertics or Minealocorticoids Receptor Antagonists:"}, 
{"Row" : 12, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF TODAY", "DisplayText" : "Chem 7 + MAG Today", "Text" : "                            Chem 7 + Magnesium (today)"},
{"Row" : 13, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 7 DAYS", "DisplayText" : "Chem 7 + Mag 7 Days", "Text" : "  Chem 7 + Magnesium (7 days)"},
{"Row" : 16, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 28 DAYS", "DisplayText" : "Chem 7 + Mag 28 Days", "Text" : "  Chem 7 + Magnesium (28 days)"},
{"Row" : 17, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 6 MONTHS", "DisplayText" : "Chem 7 + Mag 6 months", "Text" : "                      Chem 7 + Magnesium (6 months)"}
]},
{"Name" : "CHF PSZ GMENU HEART FAILURE REDUCED EF V2", "Term" : "created 4/18/23 per LEAF request #330, submitted by Crook, to improve medication management of Heart Failure and to align prescribing with VA/DoD guidelines  MTB-CAC", "DisplayText" : "Reduced EF (LVEF <= 40%) or HF with Improved EF...  ", "Version" : "CHF", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "Recommendations for Reduced EF (LVE<=40%) or HF with improved EF", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Text" : " (Order by strength of recommendation-Top to Bottom, then to next column)"}, 
{"Row" : 5, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), ACE INHIBITOR (ACEI),", "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR BLOCKER (ARB)", "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Text" : "    -Morbidity and mortality benefit"}, 
{"Row" : 8, "Column" : 1, "Text" : "    -Initiate in Stage C, NYHA Class II or III"}, 
{"Row" : 10, "Column" : 1, "Text" : "  feasible. ARB acceptable if ACEI is not feasible"}, 
{"Row" : 11, "Column" : 1, "Text" : "-Initiate an ACEI in Stage B"}, 
{"Row" : 12, "Column" : 1, "Text" : "-ARNI and ACEI contraindicated if hx of angioedema"}, 
{"Row" : 13, "Column" : 1, "Text" : "-Additional benefit in diabetes with microalbuminuria and chronic"}, 
{"Row" : 14, "Column" : 1, "Text" : " kidney disease (CKD)"}, 
{"Row" : 15, "Column" : 1, "Text" : "-Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 17, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI):"}, 
{"Row" : 18, "Column" : 1, "Text" : "   *Do not administer within 36 hours of ACEI"}, 
{"Row" : 19, "Column" : 1, "Item" : "CHF PSOZ ENTRESTO __ MG (OUTPT)", "DisplayText" : "        SACUBITRIL/VALSARTAN (ENTRESTO)", "Text" : "                 Sacubitril/valsartan __ mq (Target 97/103mg BID)"},
{"Row" : 20, "Column" : 1, "Text" : "          If no current ACEI/ARB use or if taking low dose ACEI/ARB: Initiate"}, 
{"Row" : 21, "Column" : 1, "Text" : "                               24mg/26mg"}, 
{"Row" : 22, "Column" : 1, "Text" : "          If current use of moderate dose ACEI/ARB: Initiate 49mg/51mg BID"}, 
{"Row" : 24, "Column" : 1, "Text" : "ACE INHIBITORS (ACEI):"}, 
{"Row" : 25, "Column" : 1, "Text" : "    *Failure/Contraindication to ARNI"}, 
{"Row" : 27, "Column" : 1, "Item" : "CHF PSOZ LISINOPRIL __MG DAILY (CHF)", "DisplayText" : "                 Lisinopril __mg (Initiate 2.5-5mg daily, Target 20-40mg daily)", "Text" :""},
{"Row" : 29, "Column" : 1, "Item" : "CHF PSOZ ENALAPRIL ___MG BID (CHF)", "DisplayText" : "                 Enalapril __mg (Initiate 2.5mg BID, Target 10-20mg BID)"},
{"Row" : 31, "Column" : 1, "Item" : "CHF PSOZ CAPTOPRIL __MG TID (CHF)", "DisplayText" : "                 Captopril __mg (Initiate 6.25mg TID, Target 50mg TID)", "Text" :""},
{"Row" : 36, "Column" : 1, "Item" : "CHF PSOZ LOSARTAN __MG DAILY (CHF)", "DisplayText" : "                 Losartan __mg (Initiate 25-50mg daily, Target 50-150mg daily)"},
{"Row" : 38, "Column" : 1, "Item" : "CHF PSOZ VALSARTAN __MG (CHF)", "DisplayText" : "                 Valsartan __mg (Initiate 20-40mg daily, Target 160mg BID)"},
{"Row" : 40, "Column" : 1, "Item" : "CHF PSOZ CANDESARTAN __MG DAILY (CHF)", "DisplayText" : "                 Candesartan __mg (Initiate 4-8mg daily, Target 32mg daily)"},
{"Row" : 33, "Column" : 1, "Text" : "ANGIOTENSIN RECEPTOR BLOCKER (ARB):"}, 
{"Row" : 34, "Column" : 1, "Text" : "   *Failure/Contraindication to ARNI and ACEI"}, 
{"Row" : 43, "Column" : 1, "Text" : "SGLT-2 (SODIUM GLUCOSE TRANSPORTER 2 INHIBITORS)", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "    -Mortality and hospitalization benefit"}, 
{"Row" : 45, "Column" : 1, "Text" : "    -Initiate in all Stage C symptomatic HF regardless of diabetes diagnosis"}, 
{"Row" : 46, "Column" : 1, "Text" : "    -Initiate in Stage A in patients with T2DM with either established CVD"}, 
{"Row" : 47, "Column" : 1, "Text" : "        or high CV risk"}, 
{"Row" : 48, "Column" : 1, "Text" : "    -Contraindicated for dialysis, pregnant/nursing, DM-1, high risk for"}, 
{"Row" : 49, "Column" : 1, "Text" : "        ketoacidosis, hx of (pancreatic surgery, pancreatitis, or alochol abuse)"}, 
{"Row" : 50, "Column" : 1, "Text" : "    -Increased risk of UTIs and genital mycotic infections"}, 
{"Row" : 51, "Column" : 1, "Text" : "    -Reduced efficacy with eGFR <20"}, 
{"Row" : 53, "Column" : 1, "Item" : "CHF PSOZ EMPAGLIFLOZIN 12.5MG PO DAILY", "DisplayText" : "            Empagliflozin 12.5mg (Target 12.5mg daily)"},
{"Row" : 7, "Column" : 3, "Text" : "-SGLT-2i, ACEI, ARB, ARNI:"}, 
{"Row" : 15, "Column" : 3, "Text" : "                                -Mineralocorticoid Receptor Antagonists:"}, 
{"Row" : 5, "Column" : 2, "Text" : "BETA BLOCKERS", "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Text" : "    -Mortality and hospitalization benefit"}, 
{"Row" : 7, "Column" : 2, "Text" : "    -Initiate in Stage B and Stage C"}, 
{"Row" : 8, "Column" : 2, "Text" : "    -Avoid/use caution with 2nd/3rd degree heart block"}, 
{"Row" : 9, "Column" : 2, "Text" : "    -Caution with resting bradycardia"}, 
{"Row" : 11, "Column" : 2, "Item" : "CHF PSOZ CARVEDILOL __MG BID (CHF)", "DisplayText" : "                 Carvedilol __mg (Initiate 3.125mg BID)", "Text" :""},
{"Row" : 9, "Column" : 1, "Text" : "-ARNI preferred over ACEI or ARB. ACEI acceptable if ANRI is not"}, 
{"Row" : 12, "Column" : 2, "Text" : "                      If weight <=85kg: Target 25mg BID"}, 
{"Row" : 13, "Column" : 2, "Text" : "                      If weight >85kg: Target 50mg BID"}, 
{"Row" : 17, "Column" : 2, "Text" : "-If failed carvedilol and metoprolol:"}, 
{"Row" : 19, "Column" : 2, "Text" : "                                          Note: smallest commercially available tablet strength is 5mg"}, 
{"Row" : 15, "Column" : 2, "Item" : "CHF PSOZ METOPROLOL SUCCINATE __MG DAILY (CHF)", "DisplayText" : "                 Metoprolol Succinate __mg (Initiate 12.5mg - 25mg daily, Target 200mg)"},
{"Row" : 18, "Column" : 2, "Item" : "CHF PSOZ BISOPROLOL __MG DAILY (CHF)", "DisplayText" : "                 Bisoprolol __mg (Initiate 1.25mg daily, Target 10mg)"},
{"Row" : 22, "Column" : 2, "Text" : "MINERALOCORTICOID RECEPTOR ANTAGONISTS", "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Text" : "    -Morbidity and mortality benefit"}, 
{"Row" : 24, "Column" : 2, "Text" : "    -Initiate in Stage C NYHA Class II-IV"}, 
{"Row" : 25, "Column" : 2, "Text" : "    -Use not recommended for GFR<30 (clinical trials excluded patients with"}, 
{"Row" : 26, "Column" : 2, "Text" : "        serum creatinine =2.5 mg/dL) or baseline K+ >5"}, 
{"Row" : 27, "Column" : 2, "Text" : "    -Monitor K+ closely especially if also on ARNI, ACEI, or ARB"}, 
{"Row" : 28, "Column" : 2, "Text" : "    -Avoid in pregnancy or planning pregnancy"}, 
{"Row" : 32, "Column" : 2, "Text" : "    -If unable to use spironolactone due to gynecomastia or sexual side effects:"}, 
{"Row" : 30, "Column" : 2, "Item" : "CHF PSOZ SPIRONOLACTONE __MG DAILY (CHF)", "DisplayText" : "                 Spironolactone __mg (Initiate 12.5-25mg daily, Target 25-50mg daily)", "Text" :""},
{"Row" : 34, "Column" : 2, "Item" : "CHF PSOZ EPLERENONE __MG DAILY (CHF)", "DisplayText" : "                 Eplerenone __mg (Initiate 25mg daily, Target 50mg daily)", "Text" :""},
{"Row" : 37, "Column" : 2, "Text" : "Other Medication Treatments:", "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Text" : "LOOP DIURETICS", "Header" : 1}, 
{"Row" : 40, "Column" : 2, "Text" : "                       -Symptom benefit"}, 
{"Row" : 41, "Column" : 2, "Text" : "    -Preferred diuretic for most patients with fluid retention and congestive"}, 
{"Row" : 42, "Column" : 2, "Text" : "        symptoms"}, 
{"Row" : 43, "Column" : 2, "Text" : "    -May cause dehydration"}, 
{"Row" : 44, "Column" : 2, "Text" : "    -Monitor K+ and electrolytes closely"}, 
{"Row" : 45, "Column" : 2, "Text" : "-May use thiazide instead of a loop if patient is also hypertensive and only"}, 
{"Row" : 46, "Column" : 2, "Text" : "   mild fluid retention, if CrCl>30"}, 
{"Row" : 48, "Column" : 2, "Item" : "CHF PSOZ FUROSEMIDE __MG (CHF)", "DisplayText" : "                 Furosemide __mg (Initiate 20-40mg daily or BID, Max 600mg/day)", "Text" :""},
{"Row" : 50, "Column" : 2, "Item" : "CHF PSOZ BUMETANIDE __MG (CHF)", "DisplayText" : "                 Bumetanide __mg (Initiate 0.5-1mg daily or BID, Max 10mg/day)"},
{"Row" : 52, "Column" : 2, "Text" : "    -If failed furosemide and bumetanide:"}, 
{"Row" : 55, "Column" : 2, "Text" : "    -If no response to moderate-high dose loop diuretic:"}, 
{"Row" : 53, "Column" : 2, "Item" : "CHF GMRCZ PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "DisplayText" : "PRIOR AUTHORIZATION DRUG REQUEST (OUTPATIENT)", "Text" : "        PADR for torsemide"},
{"Row" : 56, "Column" : 2, "Item" : "CHF PSOZ METOLAZONE __MG (CHF)", "DisplayText" : "                 Metolazone __mg (Initiate 2.5mg 2-3 time a week)"},
{"Row" : 5, "Column" : 3, "Text" : "LABS (baseline and after initiation/change):", "Header" : 1}, 
{"Row" : 8, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) TODAY", "DisplayText" : "Chem 7 (today)", "Text" : " Chem 7 (today)"},
{"Row" : 9, "Column" : 3, "Item" : "CHF LRTZ CHEM8(SP) 7 DAYS", "DisplayText" : "Chem 7 (7 days)", "Text" : " Chem 7 (7 days)"},
{"Row" : 11, "Column" : 3, "Text" : "                      -Loop diuretics or Mineralocorticoids Receptor Antagonists:"}, 
{"Row" : 12, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF TODAY", "DisplayText" : "Chem 7 + MAG Today", "Text" : "   Chem 7 + Magnesium (today)"},
{"Row" : 13, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 7 DAYS", "DisplayText" : "Chem 7 + Mag 7 Days", "Text" : "   Chem 7 + Magnesium (7 days)"},
{"Row" : 16, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 28 DAYS", "DisplayText" : "Chem 7 + Mag 28 Days", "Text" : "   Chem 7 + Magnesium (28 days)"},
{"Row" : 17, "Column" : 3, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 6 MONTHS", "DisplayText" : "Chem 7 + Mag 6 months", "Text" : "                        Chem 7 + Magnesium (6 months)"}
]},
{"Name" : "CHF PSZ GMENU HEART FAILURE MANAGEMENT MENU", "Term" : "created 4/18/23 per LEAF request #330, submitted by Crook, to improve medication management of Heart Failure and to align prescribing with VA/DoD guidelines  MTB-CAC", "DisplayText" : "Heart Failure Management Menu  ", "Version" : "CHF", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "Lifestyle Changes and Management of Comorbidities (strong for...)", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Text" : "-Patients should maintain a healthy lifestyle including regular physical"}, 
{"Row" : 4, "Column" : 1, "Text" : "    activity, maintaining a normal weight, healthy dietary patterns (i.e.,"}, 
{"Row" : 5, "Column" : 1, "Text" : "   Mediterranean, whole grain, plant-based, and DASH diets), and avoiding smoking"}, 
{"Row" : 6, "Column" : 1, "Text" : "    -Manage hypertension and titrate goal-directed medical therapy to  maximally"}, 
{"Row" : 7, "Column" : 1, "Text" : "        tolerated target doses (morbidity benefit in Preserved EF)"}, 
{"Row" : 8, "Column" : 1, "Text" : "    -In patients with suspicion of sleep-disordered breathing, conduct a formal"}, 
{"Row" : 9, "Column" : 1, "Text" : "        sleep assessment to diagnose/differentiate between obstructive and central"}, 
{"Row" : 10, "Column" : 1, "Text" :      "   sleep apnea (level 2a recommendation)"}, 
{"Row" : 11, "Column" : 1, "Text" : "    -In patients with obstructive sleep apnea, consider using a CPAP machine to"}, 
{"Row" : 12, "Column" : 1, "Text" : "        improve sleep quality and decrease daytime sleepiness (level 2a recommendation)"}, 
{"Row" : 13, "Column" : 1, "Text" : "    -Manage atrial fibrillation, if present, for symptom improvement (level 2a"}, 
{"Row" : 14, "Column" : 1, "Text" : "        recommendation for Preserved EF)"}, 
{"Row" : 17, "Column" : 1, "Text" : "Guideline Directed Medical Medication Management Recommendations For:", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "-SGLT-2i, ACEI, ARB, ARNI:"}, 
{"Row" : 37, "Column" : 1, "Text" : "-Mineralocorticoid Receptor Antagonists:"}, 
{"Row" : 1, "Column" : 2, "Text" : "REFERRALS:", "Header" : 1}, 
{"Row" : 3, "Column" : 2, "Item" : "CHF GMRCZ PROSTHETICS & SENSORY AIDS REQUEST", "DisplayText" : "PROSTHETICS & SENSORY AIDS REQUEST", "Text" : "BP cuff"},
{"Row" : 4, "Column" : 2, "Item" : "CHF GMRCZ PROSTHETICS & SENSORY AIDS REQUEST", "DisplayText" : "PROSTHETICS & SENSORY AIDS REQUEST", "Text" : "Scale"},
{"Row" : 5, "Column" : 2, "Item" : "CHF GMRCZ NUTRITION EDUCATION CONSULT OUTPATIENT", "DisplayText" : "NUTRITION EDUCATION/MEDICAL NUTRITION THERAPY CONSULT OUTPATIENT", "Text" : "Nutrition Consult"},
{"Row" : 6, "Column" : 2, "Item" : "CHF GMRCZ HOME TELEHEALTH ENROLLMENT OUTPT", "DisplayText" : "CCHT/HOME TELEHEALTH", "Text" : "Home Telehealth"},
{"Row" : 7, "Column" : 2, "Item" : "CHF GMRCTZ WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "WEIGHT MANAGMENT OUTPATIENT CONSULT", "Text" : "Weight Management"},
{"Row" : 8, "Column" : 2, "Item" : "CHF GMRCTZ TOBACCO CESSATION PROGRAM OUTPATIENT CONSULT", "DisplayText" : "TOBACCO CESSATION PROGRAM OUTPATIENT CONSULT", "Text" : "Tobacco Cessation"},
{"Row" : 9, "Column" : 2, "Item" : "CHF GMRCTZ HOME-BASED CARDIAC REHAB OUTPT CONSULT", "DisplayText" : "Home-Based Cardiac Rehab Outpt Consult", "Text" : "Home-Based Cardiac Rehab (1a recommendation)"},
{"Row" : 10, "Column" : 2, "Item" : "CHF GMRCZ SLEEP MEDICINE CONSULT OUTPT", "DisplayText" : "SLEEP MEDICINE CONSULT OUTPT", "Text" : "Sleep Medicine Consult Outpatient"},
{"Row" : 11, "Column" : 2, "Item" : "CHF GMRCZ ECHOCARDIOGRAM CONSULT OUTPT", "DisplayText" : "ECHOCARDIOGRAM CONSULT OUTPT", "Text" : "Echocardiogram"},
{"Row" : 12, "Column" : 2, "Item" : "CHF GMRCZ MEDICINE CARDIOLOGY CONSULT OUTPT", "DisplayText" : "MEDICINE CARDIOLOGY CONSULT OUTPT", "Text" : "Cardiology Outpatient"},
{"Row" : 13, "Column" : 2, "Item" : "CHF GMRCTZ PALLIATIVE CARE CONSULT OUTPATIENT", "DisplayText" : "PALLIATIVE CARE CONSULT", "Text" : "Palliative Care Outpatient-Stage D"},
{"Row" : 17, "Column" : 2, "Text" : "CHF Stages for Reference:", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "Stage A: Risk factors for HF present (but no current symptoms/signs)"}, 
{"Row" : 21, "Column" : 2, "Text" : "Stage B (Pre-Heart Failure): No current or previous symptoms, but evidence of"}, 
{"Row" : 22, "Column" : 2, "Text" : " any of the following: structural heart disease, evidence of increased filling"}, 
{"Row" : 23, "Column" : 2, "Text" : " pressures, risk factors + (increased natriuretic peptide levels or elevated"}, 
{"Row" : 24, "Column" : 2, "Text" : " troponin in absence of competing diagnosis)"}, 
{"Row" : 26, "Column" : 2, "Text" : "Stage C (Symptomatic Heart Failure): Current or previous symptoms/signs of HF"}, 
{"Row" : 28, "Column" : 2, "Text" : "Stage D (Advanced Heart Failure): Marked HF that interfere with daily life and"}, 
{"Row" : 29, "Column" : 2, "Text" : " with recurrent hospitalizations despite attempts to optimize GDMT"}, 
{"Row" : 19, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE PRESERVED EF V2", "DisplayText" : "Heart Failure Management - Recommendations for Preserved EF", "Text" : "Preserved EF (LVEF >= 50%)..."},
{"Row" : 23, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE MILDLY-REDUCED EF v2", "DisplayText" : "Heart Failure Management Recommendations for Mildly-reduced EF", "Text" : "Mildly-reduced EF (LVEF 41-49%)..."},
{"Row" : 21, "Column" : 1, "Item" : "CHF PSZ GMENU HEART FAILURE REDUCED EF V2", "DisplayText" : "Reduced EF (LVEF <= 40%) or HF with Improved EF..."},
{"Row" : 27, "Column" : 1, "Text" : "LABS (baseline and after initiation/change):", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "CHF LRTZ CHEM8(SP) TODAY", "DisplayText" : " Chem 7 (today)", "Text" : "  Chem 7 (today)"},
{"Row" : 31, "Column" : 1, "Item" : "CHF LRTZ CHEM8(SP) 7 DAYS", "DisplayText" : " Chem 7 (7 days)", "Text" : "  Chem 7 (7 days)"},
{"Row" : 33, "Column" : 1, "Text" : "-Loop diuretics or Mineralocorticoids Receptor Antagonists:"}, 
{"Row" : 34, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF TODAY", "DisplayText" : " Chem 7 + MAG Today", "Text" : "  Chem 7 + Magnesium (today)"},
{"Row" : 35, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 7 DAYS", "DisplayText" : " Chem 7 + Mag 7 Days", "Text" : "  Chem 7 + Magnesium (7 days)"},
{"Row" : 38, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 28 DAYS", "DisplayText" : " Chem 7 + Mag 28 Days", "Text" : " Chem 7 + Magnesium (28 days)"},
{"Row" : 39, "Column" : 1, "Item" : "CHF ORZ SET CHEM 7 + MAG CHF 6 MONTHS", "DisplayText" : " Chem 7 + Mag 6 months", "Text" : "  Chem 7 + Magnesium (6 months)"}
]}
]
